프로티아

303360KOSDAQ의료용 기기 제조업

74.5 / 100

Reference Date: 2026-04-13

Financial Score31.5 / 40

News Sentiment20.0 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

ProTia develops, manufactures, and sells in vitro diagnostic medical devices based on immune diagnostic technology, specializing in allergy, food intolerance, and antibiotic susceptibility tests. The company holds over 45% market share domestically and has expanded to 68 countries globally. It continuously innovates through its in-house research institute, earning three Yangsil Awards and four NET technology certifications from the government.

Number of Employees

113people

Average Salary

41.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

14.37Industry Average 26.526.5Point

Lower than industry avg (good)

PBR

2.09Industry Average 1.702.5Point

Higher than industry avg (caution)

ROE

15.72Industry Average 8.005.5Point

2.0x industry avg (good)

Debt Ratio

1.33Industry Average 10.958.0Point

Half of industry avg (excellent)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲35.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲481.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.3% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Positive
프로티아, PLA 기술로 176종 알레르기 진단 '한 번에'
프로티아는 독자적인 PLA 특허 기술로 세계 최다 176종 알레르기 유발물질을 한 번에 진단할 수 있는 제품을 개발하여 글로벌 시장 진출을 확대할 계획입니다.
Positive
“176종 알레르기 한번에 찾아낸다"
프로티아는 다중진단 기술 특허를 통해 글로벌 경쟁사 대비 3배 수준의 알레르기 진단 능력을 보유하고 있으며, 동물용 체외진단 키트 개발에도 나섰습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (56%)

Current 4,985Won52-week high 6,55052-week low 2,965

1-month return3.0Point

1m 0.81% (flat)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-30
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26